Enrollment of 80mg PK Run-In Cohort in Ph 2 EVANGELINE Trial of (Z)-Endoxifen as a Neoadjuvant Treatment for ER+ / HER2- Breast Cancer Completed
“Full enrollment of the 80mg pharmacokinetic run-in cohort of the EVANGELINE study is yet another important milestone in our ambitious (Z)-endoxifen development program,” said Steven Quay, M.D., Ph.D., Atossa’s President and Chief Executive Officer. “Based on data from the 40mg cohort and a review of safety, efficacy and PK data from participants enrolled earlier in the 80mg PK run-in cohort, we are confident that the 80mg dose will be well tolerated and deliver the optimal concentration levels to fully target PKCβ1 inhibition. We look forward to opening the treatment arm of this important study and bringing this potentially transformative treatment to women diagnosed with breast cancer as quickly as possible.”
Share:
More News
“The initial efficacy data from the Part C studies are consistent with the encouraging efficacy signals we previously reported for Parts A and B of THIO-101, including an 88% disease control rate in third-line NSCLC patients. This measure of efficacy is close to triple the reported outcome for standard-of-care chemotherapy
“Patients with non-muscle invasive bladder cancer continue to face a significant risk of disease recurrence despite available treatment options,” said Mark Schoenberg, M.D., Chief Medical Officer of UroGen. “UGN-501 is an investigational next-generation oncolytic virus designed to selectively destroy tumor cells while generating an anti-tumor immune response. FDA clearance of
“Whitehawk has established strong expertise in ADC technology and oncology drug development,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “This collaboration further expands the application of Biocytogen’s fully human bispecific antibodies in ADC development. We look forward to supporting the efficient advancement of multiple programs by contributing high-quality
Hesham Abdullah, Senior Vice President, Global Head Oncology, R&D, GSK, said: “The AZUR-1 results support the potential for dostarlimab to transform treatment for dMMR/MSI-H locally advanced rectal cancer. For many patients today, rectal cancer treatment comes with the tolerability burden and lasting impacts from chemotherapy, radiation and surgery. These data